by Annie De Groot | May 11, 2013 | Thinking Out Loud -Blog
Low immunogenicity predicted for emerging avian-origin H7N9: Implication for influenza vaccine design Volume 9, Issue 5 May 2013 Keywords: Emerging Infectious Diseases, H7N9, Immunoinformatics, Influenza, T Cell Epitope, Vaccine, Vaccine Design Authors: Anne S. De...
by Annie De Groot | May 11, 2013 | Events
EpiVax will be at the 11th Annual EID and Biodefense Meeting, June 17-19, 2013 at the Almas Temple Club, Washington, DC. Dr. Annie De Groot will be joining a panel of vaccine and influenza experts to discuss pandemic universal influenza vaccines. See EID and...
by Annie De Groot | Apr 16, 2013 | News, Thinking Out Loud -Blog
An Update on EpiVax’ H7N9 “FastVax” Progress EpiVax scientists are currently in discussions with groups in China, Canada and the US about producing a vaccine. Here we highlight a few key points about the current progress of EpiVax’ FastVax...
by Annie De Groot | Apr 16, 2013 | News
Providence Business News Article: life sciences EpiVax, partners move ahead on H7N9 flu vaccine production COURTESY UNIVERSITY OF RHODE ISLAND EPIVAX, the life sciences company founded by Dr. Anne S. De Groot, is engaged in pioneering efforts with Aldevron, a life...
by Annie De Groot | Apr 12, 2013 | News, Thinking Out Loud -Blog
Is H7N9 influenza a ‘Stealth’ virus? What we found: The bioinformatics team at EpiVax examined H7N9 (Shanghai 2013) sequence and found an unusually low number of T cell epitopes (see figure below). We predict that it will be difficult to make...